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We analyzed the subgross distribution of the invasive component in 875 consecutive cases of breast carcinomas using large-format
histology sections and compared the immunophenotype (estrogen and progesterone receptor expression, HER2 overexpression
and expression of basal-like markers, CK5/6, CK14, and epidermal growth factor receptor) in unifocal, multifocal, and diﬀuse
tumors. Histology grade and lymph node status were also analyzed. Unifocal invasive carcinomas comprised 58.6% (513/875),
multifocal invasive carcinomas 36.5% (319/875), and diﬀuse invasive carcinomas 4.9% (43/875) of the cases. The proportion of
lymph node-positive cases was signiﬁcantly higher in multifocal and diﬀuse carcinomas compared to unifocal cancers, but no
other statistically signiﬁcant diﬀerences could be veriﬁed between these tumor categories. Histological multifocality and diﬀuse
distribution of the invasive tumor component seem to be negative morphologic prognostic parameters in breast carcinomas,
independent of the molecular phenotype.
1.Introduction
Breast carcinoma is a heterogeneous group of diseases; indi-
vidual cases deviate from each other in morphology, pheno-
type, and prognosis. Using DNA microarray technique and
cluster analysis, ﬁve distinct genetic types of the disease were
delineated: luminal A, luminal B, HER2 positive, basal-like,
and normal breast like tumors [1, 2]. These tumor subtypes
can also be identiﬁed with suﬃcient accuracy during routine
diagnosis, using a simple panel of immunohistochemical
markers, including antibodies tracing estrogen receptors
(ER), progesterone receptors (PR), c-erbB-2 oncoprotein
overexpression (HER2), and some myoepithelial markers [3,
4]. The recommended myoepithelial markers for delineating
the basal-like tumors vary in diﬀerent studies, cytokeratin
(CK)5/6, CK14, CK17, and/or epidermal growth factor
receptor (EGFR) being used most often [3, 5–8]. Signiﬁcant
diﬀerences in survival of patients with diﬀerent molecular
subtypes of breast carcinoma have been recently evidenced;
Luminal A tumors have a signiﬁcantly better 5- and 10-year
survival compared to luminal B, HER2 positive, basal-like,
and unclassiﬁed tumors [9].
Using large-format histologic sections in diagnostic
routine, we have repeatedly evidenced that breast carcinoma
has a complex subgross morphology with a considerable
proportion of the tumors being either multifocal or diﬀuse
[10–13]. The most recent studies on breast cancer multi-
focality indicate that multifocality and diﬀuse distribution
of the invasive tumor component represent survival-related
negative prognostic parameters [14–17]. As we have not
found corresponding data in the literature, we designed
the present study with the aim to analyze the relation of
subgross appearance of the lesions (unifocal, multifocal, or
diﬀuse distribution of the invasive component) and some
phenotypic tumor features, such as ER, PR, and HER2
expression, basal-like phenotype, and histology grade. We
focused on the invasive component of the tumor and did
not analyze the distribution of the in situ ductal or lobular2 Pathology Research International
components in this study. We also tested the relation of the
subgross histologic distribution of the lesions to presence of
lymph node metastasis (LNM).
2.MaterialsandMethods
2.1. Study Population. This study is a retrospective analysis
of 875 consecutive breast carcinoma cases diagnosed at
the Department of Pathology and Clinical Cytology of
the Central Hospital in Falun, Sweden, during the period
January 2005−December 2009. Patients with recurrent
breast carcinomas that were diagnosed before the study
period were excluded. We also excluded purely in situ
carcinomas (132 cases), microinvasive (<1mm) carcinomas,
and carcinomas which were not routinely stained for the
immunohistochemical markers listed below. The subgross
parameters, histology grade, LNM, ER, PR, and HER2 status
were analyzed during the entire study period. The basal-like
phenotype was routinely assessed from September 2006 to
the end of the study period. The study was approved by the
Regional Ethical Committee in Uppsala-¨ Orebro region.
2.2. Large-Section Histopathology. All specimens were pre-
pared by the method of large-section histopathology, which
has been a routine procedure in our laboratory since 1982.
The method has been described in detail elsewhere [18].
Brieﬂy, all cases were discussed by a preoperative tumor
board, and the radiological (mammography, ultrasound,
andmagneticresonanceimaging)appearancewasregistered,
including the extent and distribution. This information,
together with the whole-specimen radiograph received with
the surgical specimen, guided the pathologist during the
workup. The sector-resection specimens were sliced into
3-4mm-thick tissue slices parallel to the pectoralis fascia.
The slices were also radiographed. One to ﬁve of the most
representativeslices(measuringupto9×8cm)wereselected
for embedding into large paraﬃn blocks. Larger slices were
bisected and embedded into separate blocks. Mastectomy
specimens were sliced perpendicular to the pectoralis fascia
to visualize the surgical margin in one histological plane. All
cases were discussed again on postoperative tumor board to
check the concordance of the radiological and histological
ﬁndings. Most cases which were discrepant in favour of
radiology ﬁndings were solved with additional sampling of
the specimen for histological analysis.
2.3. Immunohistochemistry. The largest invasive tumor focus
was sampled for routine immunostaining. The follow-
ing antibodies were used: ER (Ventana Medical Systems,
clone:SP1,1:200),PR(Dako,clone:PgR636,1:50),CK5/6
(Dako, clone: D5/16 B4, 1:100), CK14 (Novocastra, clone:
LL002, 1:20), EGFR (Dako, clone: E 30, 1:25), and HER2
(Dako, code A 0485, 1:250). Additional foci were only
stained in selected cases. Nuclear staining >10% of the
tumor cells were the criterion of ER and PR positivity,
cytoplasmicstainingin>10%forCK5/6andCK14positivity,
and membranous and cytoplasmic staining in >10% of the
tumorcellsforEGFRpositivity.HER2positivitywasassessed
in accordance with the criteria of the manufacturer; all 2+
equivocal cases underwent ﬂuorescence in situ hybridisation
test.
2.4. Diagnostic Criteria. The distributions of the invasive
component and of the in situ component of the same lesion
were determined separately. For the purpose of the present
study, the tumors were classiﬁed based on the distribution of
the invasive lesions. They were considered to be “unifocal”
i fo n l yo n ei n v a s i v ef o c u sc o u l db eo b s e r v e di nt h el a r g e
sections, with the tumor focus containing or not containing
an in situ component. “Multifocal” invasive lesions were
characterized by the presence of multiple well-delineated
invasive tumor foci separated from each other by uninvolved
breast tissue, regardless of the distance between the foci.
Tumors that were dispersed over a large area in the section,
much like a spider’s web, with no distinct tumor mass were
classiﬁedas“diﬀuse.”Thesizeofthediﬀusetumorswasequal
to the extent of the disease in many cases and was rather
comparable to the extent of the disease in multifocal cases
than to the size of the individual foci. When the distribution
of the lesions was assessed, in each case, an attempt was
madetosummarizetheﬁndingsindiﬀerentlevelsofthelarge
sectionstoreconstructtheinvivosituationbeforeoperation.
Detailed correlation between radiological and pathological
ﬁndings was essential. If a secondary surgical intervention
was performed in addition to the primary sector resection,
an attempt was made to summarize the ﬁndings in the entire
excised tissue. However, sector resection specimens (average
size of 9 × 6cm)weresuﬃcient for categorizing the ﬁndings
in most cases. Typical cases of unifocal, multifocal, and
diﬀuse invasive breast carcinomas are illustrated in Figure 1.
LNM was deﬁned as presence of metastatic deposit(s)
in at least one of the lymph nodes of the case, irrespective
on the size of the deposit(s). Both sentinel and nonsentinel
nodes were assessed on routinely stained sections. The
sentinel lymph nodes were additionally stained on CK8/18
(BD Biosciences, clone Cam 5.2, 1:50). Tumors expressing
at least one of the basal (myoepithelial) markers (CK5/6,
CK14, EGFR) in at least one of the invasive tumor foci
werecategorizedasbasal-liketumors.Triple-negativetumors
were deﬁned as negative for all of the following markers:
ER, PR, and HER2. The tumors were graded according to
the Notthingham (Bloom-Richardson-Elston-Ellis) grading
system [19]. Tumor size was deﬁned as the largest dimension
of the largest invasive focus.
2.5. Study Execution. All of the large histological sections
belonging to this series (average number of sections per
case 6, range of 1–34) were reviewed for the purposes
of postoperative tumor board. Histological data, including
the distribution of lesions, were determined according to
the diagnostic criteria described above and registered in a
database. “Multicentricity,” which is deﬁned as the presence
of malignant structures in diﬀerent quadrants of the same
breast, was not analyzed because it represents a clinical
and/or radiological parameter. Phenotypic parameters were
obtained from the department’s database. The statistical
analysis (comparison of proportion using chi-square test)Pathology Research International 3
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Figure 1: Typical cases of unifocal (left), multifocal (central), and diﬀuse (right) invasive breast carcinomas documented in large-format
histology sections. The lesions are marked in the lower images.
Table 1: Immunophenotypic parameters, histology grade and node status by invasive tumor distribution (unifocal, multifocal, and diﬀuse)
in 875 consecutive breast cancer cases, Falun 2005–2009.
Phenotype Invasive tumor distribution Signiﬁcance level
Unifocal Multifocal Diﬀuse Total Unifocal versus multifocal Unifocal versus diﬀuse
ER positive 83.1% (423/509) 81.8% (256/313) 97.7% (42/43) 83.4% (721/865) P = .7852 P = .0178
PR positive 66.3% (331/499) 64.9% (203/313) 53.5% (23/43) 65.1% (557/855) P = .8289 P = .1565
HER2 positive 9.6% (48/501) 15.2% (48/315) 4.8% (2/42) 11.4% (98/858) P = .0419 P = .4334
Triple negative 11.2% (56/499) 10.5% (33/313) 2.4% (1/42) 10.5% (90/854) P = .9083 P = .1144
Basal-like 12.5% (37/296) 11.3% (22/195) 3.7% (1/27) 11.6% (60/518) P = .6020 P = .2896
Grade 3 22.6% (115/509) 25.2% (80/318) 7.0% (3/43) 22.8% (198/870) P = .5664 P = .0245
Node positive 27.3% (140/513) 54.2% (173/319) 55.8% (24/43) 38.5% (337/875) P<. 0001 P = .0001
was carried out using commercially available software (Med-
Calc statistics for biomedical research, MedCalc Software,
Belgium), with P-values <.01 regarded signiﬁcant.
3. Results
The distribution of the invasive lesions could be accurately
analyzed in 875 invasive cases. Unifocal invasive carcinomas
comprised 58.6% (513/875), multifocal invasive carcinomas
36.5% (319/875), and diﬀuse invasive carcinomas 4.9%
(43/875) of the cases.
Histology grade was determined in 870 of the inva-
sive carcinomas of which 22.8% (198/870) were grade 3.
As demonstrated in Table 1, there were 115 unifocal, 80
multifocal, and 3 diﬀuse grade 3 invasive carcinomas. The
percentage of unifocal and multifocal grade 3 cases were very
similar (22.6% versus 25.2%). The proportion of grade 3
cases among diﬀuse invasive carcinomas was only 7.0%, but
the diﬀerence was not statistically signiﬁcant as only 3 such
cases were found.
Tumor size could be accurately assessed in 511 unifocal
(average size 16.0mm, range 3–70mm), 315 multifocal
(average size 19.5mm, range 2–60mm), and in 41 diﬀuse
(average size 45.6mm, range 20–85mm) invasive carcino-
mas. This diﬀerence was not statistically signiﬁcant when
unifocal and multifocal tumors were compared (P = .7375),
butthediﬀerencesbecamesigniﬁcantwhenthediﬀusegroup
was added to analysis (P = .0003).
ER status was assessed in 865 invasive breast carcino-
mas. There were 83.4% (721/865) ER-positive and 16.6%4 Pathology Research International
(144/865) ER-negative cases. There were 83.1% (423/509)
unifocal, 81.8% (256/313) multifocal, and 97.7% (42/43)
diﬀuse ER-positive invasive cancers. The diﬀerences were
statistically not signiﬁcant.
PRwasassessedin855cases.Therewere65.1%(557/855)
PR-positive and 34.9% (298/855) PR-negative cases. 66.3%
(331/499) of the unifocal, 64.9% (203/313) of the multifocal,
and 53.5% (23/43) of the diﬀuse invasive carcinomas were
PR positive. The diﬀerences were statistically not signiﬁcant.
During the study period, 858 invasive breast carcinomas
were tested for HER2 overexpression and 11.4% (98/858)
were found to be HER2 positive: 9.6% (48/501) unifocal,
15.2% (48/315) multifocal, and 4.8% (2/42) diﬀuse tumors.
The diﬀerences were statistically not signiﬁcant.
The proportion of triple negative cases was 10.5%
(90/854) in the present series, 11.2% (56/499) among
the unifocal, 10.5% (33/313) among the multifocal, and
2.4% (1/42) among the diﬀuse cases. The diﬀerences were
statistically not signiﬁcant.
Carcinomas were routinely stained for basal markers in
518 cases. Of those, 11.6% (60/518) expressed basal-like
phenotype, 12.5% (37/296) of the unifocal, 11.3% (22/195)
of the multifocal, and 3.7% (1/27) of the diﬀuse tumors. The
diﬀerences were statistically not signiﬁcant.
LNM was determined in all cases of the present series
of invasive breast carcinomas and 38.5% (337/875) of
the cases had some form of metastatic tumor spread
(including macrometastases, micrometastases, and isolated
cancer cells/cellgroups). The proportion of lymph node
positive cases was 27.3% (140/513) in the group of unifocal
cancers, 54.2% (173/319) in the group of multifocal cancers,
and 55.8% (24/43) in the group of diﬀuse tumors. These
diﬀerences were statistically highly signiﬁcant.
4. Discussion
Breast cancer is a disease with wide variation in subgross
morphology. Tumor multifocality has been evidenced in a
substantial proportion of the cases in early whole organ
studiesandisseenin>30%intheseriesofcasesdocumented
with large-format histology slides [10–13]. In addition, 5%
of the invasive carcinomas exhibit a diﬀuse, spider’s web-like
growth pattern [14]. Modern radiology methods, especially
if used in combination (multimodality approach), are able
to indicate the growth pattern of the tumor in the vast
majority of the cases [18]. Detailed radiological-pathological
correlation and regular use of large-format histology slides
enables the breast pathologist to correctly assess tumor size,
disease extent, and multifocality or diﬀuse growth and to
conﬁrm or correct the preoperative radiological results.
The prognostic signiﬁcance of tumor multifocality has
recently received special attention as, in contrast to some
previous publications [20], recent long-term followup stud-
ies have demonstrated signiﬁcantly lower breast cancer-
speciﬁc survival in multifocal than in unifocal tumors
[15–17]. Multifocality seems to be a negative morphologic
parameter independent of treatmentmodalities [16].Diﬀuse
invasive carcinomas have an even worse prognosis than the
multifocal tumors [14, 17]. The question arises whether
diﬀerences in survival between unifocal, multifocal, and
diﬀuse breast carcinomas can be explained with diﬀerences
in their molecular phenotype. The present study was carried
out on a recent series of cases, thus survival of the patients
could not be tested.
The greater metastatic capacity of multifocal and diﬀuse
tumors compared to the unifocal ones has been repeatedly
proven in independent studies [10–12, 20–22] and was also
conﬁrmed in the present study. In fact, this was the only
statistically signiﬁcant diﬀerence between unifocal versus
multifocal and unifocal versus diﬀuse invasive carcinomas in
the present series.
The relation of tumor multifocality and tumor pheno-
type is rarely studied in the literature. Histology grade, ER,
PR, and HER2 status represent well-established, routinely
assessed morphological prognostic parameters [23, 24].
According to our results, no signiﬁcant diﬀerences could be
demonstrated between these tumor categories with respect
to histology grade, ER, PR, and HER2 status. The same
ﬁnding has been reported by Litton et al., but their study was
limited to women ≤35 years [25]. In the study of Oh et al.,
no signiﬁcant diﬀerences were found between unifocal and
multifocal/multicentric tumors regarding nuclear grade and
ER status [26].
While multifocal breast carcinomas had a tendency to
show more unfavourable phenotype, although statistically
not signiﬁcantly diﬀerent, compared to the unifocal tumors,
the diﬀuse invasive carcinomas exhibited an opposite ten-
dency. They were less often ER negative, less often triple
negative, less often HER2 positive, or basal-like than the
unifocal cancers. Although this is a remarkable phenomenon
as these tumors have the less favourable outcome, this may
be explained by the high percentage of invasive lobular
carcinomas in this subgroup [10, 14].
5. Conclusion
Although multifocal and diﬀuse invasive breast carcinomas
exhibited a doubled frequency of LNM compared to that
in unifocal tumors, no statistically signiﬁcant diﬀerences
could be demonstrated between these categories regarding
histology grade, ER, PR, or HER2 status and regarding the
proportion of tumors with basal-like phenotype. Multifocal
and diﬀuse distribution of the invasive tumor component
seems to be an independent negative morphologic prognos-
tic parameter in breast cancer.
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